Johnson & Johnson (JNJ) on Monday announced a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company for $1 billion in cash.
The transaction is expected to close later this year.
The acquisition is expected to expand Johnson & Johnson's oncology pipeline with Firefly Bio's Firelink degrader antibody conjugate platform.
The deal also adds preclinical candidates targeting KRAS-driven tumors and other hard-to-treat solid cancers.
Johnson & Johnson said the Firelink platform is designed to deliver highly selective protein degraders to tumor cells while minimizing effects on healthy cells.
In the pre-market trading, Johnson & Johnson is 0.47% lesser at $231.68 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.